Sign In
Buy MGTX
$12.52
+0.310 (+2.54%)
At Close: Jul 21, 2026
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
04:30pm, Wednesday, 09'th Oct 2024
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDN
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates
08:40am, Monday, 12'th Aug 2024
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.53 per share a year ago.
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in pati
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
07:03am, Monday, 12'th Aug 2024
LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an unde
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
08:49am, Tuesday, 30'th Jul 2024
Penny stocks represent an interesting investment opportunity.
MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
11:02am, Monday, 15'th Jul 2024
Bota-vec sale to JNJ/Janssen is complete – cash & future milestones from the deal should carry MeiraGTx through the next catalysts. The partnership with Sanofi strengthens the balance sheet and help
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
08:00am, Thursday, 09'th May 2024
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024
MeiraGTx to Participate in Upcoming Investor Conferences
04:30pm, Wednesday, 24'th Apr 2024
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
04:30pm, Thursday, 18'th Apr 2024
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
10:46am, Thursday, 14'th Mar 2024
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.58 per share a year ago.
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
08:30am, Thursday, 14'th Mar 2024
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing
MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met
08:23am, Thursday, 15'th Feb 2024
Positive results achieved in phase 1/2 MGT009 study using bota-vec for the treatment of patients with XLRP; Patients given this gene therapy achieved meaningful improvement of vision. Enrollment compl
Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet
11:19am, Wednesday, 10'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 217.9% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questiona
MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions
10:32am, Wednesday, 10'th Jan 2024
MeiraGTx (MGTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
01:32pm, Tuesday, 02'nd Jan 2024
MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.
